Apparent glucose utilization in Walker 256 metastatic brain tumors.

Area of Science:

• Neuroscience
• Oncology
• Biochemistry

Background:

• Metastatic brain tumors present unique metabolic challenges.
• Understanding glucose metabolism in tumors is crucial for developing targeted therapies.

Purpose of the Study:

• To measure regional glucose utilization (GU) in metastatic Walker 256 (WL-256) brain tumors in rats.
• To investigate the relationship between GU, tumor characteristics, and surrounding brain tissue metabolism.
• To explore the diagnostic and therapeutic potential of glucose analogue uptake.

Main Methods:

• Intracarotid injection of WL-256 tumor cells in rats.
• Measurement of regional apparent glucose utilization using 14C-deoxyglucose and quantitative autoradiography.
• Assessment of local cerebral glucose utilization (LCGU) in tumor-bearing and remote brain regions.

Main Results:

• Apparent GU was uniform within small/medium non-necrotic tumors but varied significantly between tumors.
• High GU in viable tumor tissue was 1.3-3 times higher than adjacent normal brain.
• LCGU was reduced in remote gray matter, proportional to tumor burden.
• Viable tumor cells demonstrated high 2-deoxyglucose uptake.

Conclusions:

• Metastatic brain tumors exhibit significantly elevated glucose utilization compared to normal brain.
• The high uptake of 2-deoxyglucose by viable tumor cells holds diagnostic value.
• Glucose analogues could be developed for tumor-selective glycolysis inhibition and tumoricidal effects.